NYU researchers tackle racial/ethnic disparities in HIV medical studies

July 07, 2014

A New York University College of Nursing (NYUCN) research team found that a social/behavioral intervention vastly increased the number of African American and Latino individuals living with HIV/AIDS who enrolled in HIV/AIDS medical studies. The intervention, designed by researchers at the NYUCN's Center for Drug Use and HIV Research (CDUHR), found that nine out of ten participants who were found eligible for studies decided to enroll, compared to zero participants among a control group.

The study, called "ACT2," addresses a long-recognized problem: the racial/ethnic groups most affected by HIV are chronically under-represented in HIV/AIDS medical research. While 50% of all people living with HIV/AIDS are African American/Black, they comprise a mere 30% of those enrolled in HIV/AIDS medical studies. Likewise, Latinos are also under-represented in such studies in many settings. This lack of proportional representation raises a number of questions, including about the applicability of medical research findings to the groups most affected by HIV/AIDS.

"The issue of under-representation of these racial/ethnic groups is well known, but it's a complex problem and not that easy to change," said Marya Gwadz, PhD, a senior research scientist at NYUCN and lead author of the study. "Our study is the first to have tested social/behavioral intervention strategies to reduce barriers to HIV medical studies for these under-represented populations."

The ACT2 study demonstrated a thirty-fold increase in rates of screening for HIV/AIDS medical studies among African Americans and Latinos living with HIV/AIDS compared to a control group. As reported in the June 2014 issue of AIDS and Behavior, half of those screened were found eligible for a study, and among those found eligible, 90% enrolled in at least one HIV/AIDS medical study. Among participants in the control group, screening was rare and, as a result, none in the control group enrolled.

"There are misconceptions that African Americans and Latinos are not interested in HIV/AIDS medical studies," said Dr. Gwadz. "We found that members of these groups are typically fearful of medical studies and also have socioeconomic barriers to accessing them. Yet we found that in the context of the ACT2 intervention program, which allows participants to learn more about trials, articulate these fears, and gain access to trials, they are very willing to explore the possibility of participating, and if they are found eligible and the study is right for them, also eager to enroll."

The ACT2 intervention uses a potent peer-driven recruitment and peer education intervention approach, combined with brief, structured small group and individual sessions delivered by trained counselors. The sessions focused on increasing awareness about the problem of disproportionate representation of people of color in HIV/AIDS medical studies, while also allowing participants to voice fears about these studies. Fear of medical studies is common among African American and Latino populations, and is rooted in the long-standing mistreatment of people of color in U.S. medical research. Participants in the control arm received a time-matched, small-group health education program.

The researchers focused on enrollment into both therapeutic/treatment clinical trials and biomedical observational studies, which have similar rates of racial/ethnic under-representation. They found that participants were much less likely to be found eligible for trials testing new treatments or therapies for HIV/AIDS, compared to observational studies that do not involve testing new treatments.

"While social/behavioral interventions such as ACT2 are important for increasing motivation and knowledge of medical studies, and providing support to navigate the complexity of screening and enrollment into studies among this population, we believe achieving appropriate racial/ethnic representation will require modification of study inclusion criteria to increase the proportion found eligible for therapeutic studies," noted Noelle Leonard, PhD, a co-investigator of the study at CDUHR.

Both the intervention and control groups were notified about the thirty ongoing HIV/AIDS medical studies in the New York City area where the study was conducted and were presented with the option to initiate screening to determine their eligibility. As part of the intervention, participants in the ACT2 intervention group were offered help in navigating the structural and personal barriers they might encounter to completing the often-complex screening process, while those in the control group were not offered navigation.

ACT2 draws its success by incorporating both the Theory of Normative Regulation -- which posits that behaviors of individuals are amplified through their social groups -- and Motivational Interviewing, a health behavior change method for fostering individuals' intrinsic motivation to make positive changes without applying pressure or judgment.

"Our participants have told us they want to contribute to their communities through research and help those with HIV who come after them," said Dr. Gwadz. "Yet the impediments they typically experience to participating in medical studies deny them this opportunity. ACT2 helps build a bridge between HIV/AIDS medical studies and communities of color."

Of the thirty medical studies available during the study period, twenty-three (76.6%) were therapeutic studies and seven (23.4%) were observational studies. Yet despite the vast majority of the studies being therapeutic, only 4% of ACT2 participants screened were eligible for such studies. Instead, the majority of participants (84.4%) were found eligible for observational studies.

"It is imperative that scientists who develop HIV/AIDS medical studies consider the implications of highly restrictive inclusion criteria and other design features on the participation of under-represented groups, while at the same time maintaining study validity," said Dr. Leonard.

The ACT2 intervention is designed to be administered by Master's level clinicians, and is comprised of six hours of staff-guided intervention sessions, and individualized navigation during the screening process, as needed. Participants also have the opportunity to independently educate their peers about medical studies, which is in itself a form of intervention. "ACT2 does not require a great deal of staff time to implement," said Dr. Gwadz, "but can potentially make a big difference in rates of enrollment among racial/ethnic minorities." ACT2 is one of the programs in the Substance Use and Mental Health Services Administration's (SAMHSA) National Registry of Evidence-based Programs and Practices.
-end-
Study Authors:

Marya Gwadz, Charles M. Cleland, Mindy Belkin, Amanda Ritchie, Noelle Leonard, Angela Banfield, and Pablo Colon, College of Nursing, New York University, New York, NY; Marion Riedel, School of Social Work, Columbia University, New York, NY; Vanessa Elharrar and Jonathan Kagan, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD; Donna Mildvan, Division of Infectious Diseases, Mount Sinai Beth Israel Medical Center, New York, NY; and the ACT2 Collaborative Research Team.

Acknowledgements:

This study was supported by a grant from the National Institute of Allergy and Infectious Diseases (R01AI070005) and the Center for Drug Use and HIV Research (P30DA011041) at the New York University College of Nursing. The project is dedicated to the memory of Keith Cylar, MSW, Co-founder and Co-chief Executive Officer of Housing Works, Inc. We would like to thank the men and women who participated in the study, Amy Braksmajer, Ph.D. and Christopher Hilliard, MPH for editorial assistance, Dr. Usha Sharma, the study's Program Officer, and members of the ACT2 Collaborative Research Team: Michael Aguirre, Noreen Boadi, MA, DeShannon Bowens, MA, Patricia Chang, MA, Gwen Costantini, FNP-C, Rebecca de Guzman, Ph.D., Ann Marshak, Sondra Middleton, PA-C, Corinne Munoz-Plaza, MPH, Maya Tharaken, MSSW, Robert Quiles, and Mougeh Yasai, MA.

About CDUHR

The mission of the Center for Drug Use and HIV Research (CDUHR) is to end the HIV and HCV epidemics in drug using populations and their communities by conducting transdisciplinary research and disseminating its findings to inform programmatic, policy, and grass roots initiatives at the local, state, national and global levels. CDUHR is a Core Center of Excellence funded by the National Institute on Drug Abuse (Grant #P30 DA011041). It is the first center for the socio-behavioral study of substance use and HIV in the United States and is located at the New York University College of Nursing. For more information, visit http://www.cduhr.org.

About New York University College of Nursing

NYU College of Nursing is a global leader in nursing education, research, and practice. It offers a Bachelor of Science in Nursing, a Master of Science and Post-Master's Certificate Programs, a Doctor of Philosophy in Research Theory and Development, and a Doctor of Nursing Practice degree. For more information, visit http://www.nyu.edu/nursing.

New York University

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.